Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.
Alzheimer's disease is the most common type of dementia. Here, we break down what to know about this disease, including: What ...
Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...
Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and ...
The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
Groundbreaking research unveils potential link between cytomegalovirus and Alzheimer's disease, offering new hope for ...
There is a potential link between Alzheimer's disease and the herpes simplex virus-1 (HSV-1), which is a common cause for ...
healthday on MSN1d
Link Between Gum Disease, Brain Function Exists, Small Study SaysGum disease appears to disrupt brain activity, potentially increasing a person’s risk of cognitive decline.People with ...
Research reveals how herpes simplex virus-1 may contribute to Alzheimer’s disease, offering new insights into the disease’s ...
GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...
While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback